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dence interval 67-83%) of instances compared with the control method (25%, 95%CI 
17-33%), and among 83% (95%CI 76-91%) of positively-GDP-associated cancers 
compared with 17% (95%CI 9-24%) for the control method. There was no significant 
difference between the two methods for negatively-GDP-associated cancers. In 
terms of the relative magnitude of change compared to the actual incidences, there 
was no significant difference between the GDP-based forecast incidences and the 
control (mean magnitude difference 3.8%, 95% CI -3.5% - 11.0%). ConClusions: 
During epidemiological transition, cancer incidence is unlikely to remain static 
and so developing a proxy variable to evaluate risk over time is important. Using 
GDP as a proxy variable is preferable to the alternative of projecting historical 
values forward unchanged in terms of directional effect. However our study found 
no significant difference in terms of relative magnitude of the change over time. 
This latter result may be due to a small sample size of registries, indicating a need 
for further research.
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objeCtives: Bevacizumab (BEV) has proven to be efficacious to delay ovarian can-
cer progression and in controlling ascites. Significant overall survival (OS) benefits 
were reported in GOG218 patients with ascites at baseline, however, not in the ITT 
population. This raises questions about the potential role of “progression-driven 
cross-over” in confounding OS trial results. The objective of this study was to use 
decision-analytic modeling to estimate the potential impact of this “cross-over bias” 
in a RCT. Methods: A decision-analytic Markov model with 6 mutually exclu-
sive health states was built simulating OS as reported in GOG218. In the base case 
analysis, a 49 month time horizon was used (trial length). Input parameters were 
based on trial data and published literature. The model was calibrated to estimate 
the amount of patients developing ascites and switching. The model was then used 
estimating the unbiased treatment effect as it would have been observed without 
switching. Results: The model provided similar survival curves as reported. When 
switching treatment was disabled, the relative risk reduction for OS due to BEV 
compared to placebo changed from 11% to 32% over the 49 month time horizon. The 
results were sensitive to changes in the input parameter of switching, developing 
severe ascites and mortality after progression. ConClusions: Decision-analytic 
methods are suitable for describing causal relations and the impact of a potential 
bias. We estimated that about two thirds of the true treatment effect could not be 
captured in the biased data analysis. However, a formal adjustment of the original 
RCT data was not feasible due to lack of clinical trial data describing switching 
patterns. As crossover bias cannot always be avoided by trial design due to ethical 
reasons, we recommend collecting sufficient confounding variables determining 
cross-over so that specific statistical methods for causal-inference can be applied 
to control the cross-over bias.
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objeCtives: To examine the new co-payment scheme for prescribed medications 
introduced in Spain in 2012 and to explore differences in patient and National 
Health Service (NHS) drug cost co-payments between the old and the new schemes, 
using an example in a modelled patient population with coronary heart disease 
(CHD). Methods: The new legislation was researched and the new co-payment 
scheme was summarised in a flowchart. A published economic evaluation of drug-
eluting versus bare metal stents for high-risk patients with CHD was used to calcu-
late co-payments for the total cost of a prescribed drug (clopidogrel) from patients 
and from the NHS. The patient contribution was estimated from the income and 
expected work status of the model’s population. Results: In the new co-payment 
scheme, pharmacy-dispensed drugs are divided into three categories, using the 
Anatomical, Therapeutic, and Chemical classification system: 1) reimbursed with 
reduced contribution (4.26 € per prescription in 2014), 2) reimbursed without reduced 
contribution (ranging from 40% to 60%, depending on declared incomes for active 
workers, and from 10% to 60% for retired people) and 3) not reimbursed. Monthly 
limits for retired people (in 2014) range from 8.26 € to 62 € , with a monthly limit 
of 0.426 € for long-term, chronic conditions. The current, monthly, over-the-coun-
ter price of clopidogrel is 22.92 € . Under the old co-payment scheme, the model 
estimated that the average NHS payment was 19.62 € per patient (86% of the cost). 
Under the new scheme, this amount was estimated at 16.55 € (72%). The NHS con-
tribution decreased by 14%. ConClusions: The new scheme results in a signifi-
cant reduction to drug-related NHS co-payment contributions. This reduction could 
lead to significant changes in incremental cost-effectiveness ratio estimates. It is 
recommended that this adjustment be made in economic evaluations developed 
or adapted for Spain.
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objeCtives: Genetic screening identifies candidates for intensified cancer 
screening and prevention. Due to the high cost of genetic testing, it is impor-
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objeCtives: To compare homogeneous (HMM) versus non-homogeneous Markov 
models (NHMM) for cost-effectiveness analysis (CEA) of routine use of transparent 
dressings containing a chlorhexidine gluconate gel pad versus standard trans-
parent dressings. The antimicrobial dressing protects central vascular accesses 
reducing the risk of catheter-related bloodstream infections (CRBSIs) in intensive 
care units (ICU). The impact of the modeling approach on the decision of adopt-
ing antimicrobial dressings for critically-ill patients is discussed. Methods: 
Comparative clinical efficacy data from a multicentre randomized controlled trial 
(RCT) enrolling 1,879 patients and economical data from micro and macro-costing 
published studies were combined. The HMM and NHMM models were built sepa-
rately using the same sources. The statistical unit was the ICU patient and the ICU 
perspective was chosen. Probabilistic sensitivity analyses (PSA) were conducted 
for both models for comparing the robustness of the CEA results. Results: The 
difference in clinical outcomes between each dressing strategies was statisti-
cally significant with both models while cost differences were not. The PSA with 
the NHMM resulted in 11.8 infections avoided per 1,000 patients (95%CI: [3.85; 
19.64]) and a mean extra cost of € 141 per patient (95%CI: [€ -975; € 1,258]) when 
using antimicrobial dressing. The PSA with the HMM resulted in 6.45 infections 
avoided per 1,000 patients (95%CI: [0.15; 12.75]) and the mean extra cost of € 252 
per patient (95%CI: [€ -924; € 1,428]). ConClusions: The antimicrobial dressings 
are consistently more efficacious in preventing CRBSIs whatever the model used. 
The HMM is less sensitive to simulate the real life of the ICU patients. Regardless 
the model approach chosen the antimicrobial strategy is more efficacious than 
the comparator, but its probability of being cost-effective is comparatively reduced 
with the HMM. Time dependent approach (NHMM) seems to be better adapted to 
model rare events as CRBSIs.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is a major 
cause of end-stage renal disease (ESRD) affecting approximately 4 per 10,000 people 
in Europe. There is a paucity of research regarding the natural history of ADPKD 
progression. This study aimed to utilise the results of a systematic literature review 
characterising predictors of ADPKD progression to construct a natural history dis-
ease model for ADPKD. Methods: An individual patient-level lifetime simulation 
was developed in Microsoft Excel, driven by baseline and time-dependent age, esti-
mated glomerular filtration rate (eGFR) and total kidney volume (TKV). Rates of 
progression were informed by a large naturalistic study. Dialysis modality, transplant 
status and disease-specific mortality were also modelled. Relevant ADPKD compli-
cations were stratified by chronic kidney disease stages. Modification of disease 
progression rate was investigated in order to assess the potential of the model 
for evaluating treatment interventions. Results: On visual inspection, modelled 
and published eGFR trajectories for the general ADPKD patient were consistent 
(median age at ESRD of approximately 55 years). When patients are stratified by 
baseline TKV the model predicts variable rates of progression to ESRD, aligning with 
the assertion that the baseline TKV is the most important prognostic indicator for 
ADPKD progression. Modification of the risk equations to incorporate the impact of 
an intervention has shown promise to estimate important outcomes such as delay 
to ESRD. ConClusions: The model has demonstrated both face and predictive 
validity and is capable of predicting outcomes consistent with those reported in the 
ADPKD literature. It represents the first model capable of informing on important 
clinical outcomes relevant to both clinicians and patients, such as time to ESRD, 
with the potential to evaluate the long-term impact of treatment interventions on 
ADPKD progression.
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objeCtives: To validate the use of change in Gross Domestic Product per capita 
(GDP) as a proxy for forecasting change in cancer risk. Methods: Using data from 
the International Agency for Research on Cancer (IARC) and GDP data from the 
World Bank, the correlation between the incidence of five cancers (breast, prostate, 
lung, liver, and colorectal) in 147 countries for 1993-1997 (midyear 1995), and the 
corresponding GDP was calculated. We used this correlation to retrospectively 
forecast the 2005 incidence for five cancers in four cities (Cali, Colombia; Delhi, 
India; Shanghai, China; St. Petersburg, Russia). The GDP-based forecasts were com-
pared to a control assuming no change in incidence from the IARC incidence data 
for 1998-2002 (midyear 2000). The two forecast estimates with the actual reported 
IARC 2003-2007 incidence data were compared. Results: Overall, the GDP-based 
method correctly forecasts the directional change in incidence in 75% (95% confi-
